Skip to NavigationSkip to content

GlobalData

Ovarian cancer market set to smash $6.7 billion by 2025

New research from GlobalData has forecast that the worldwide market for ovarian cancer is set to expand at a compound annual growth rate (CAGR) of 14.4% from its 2018 valuation of $1.8 billion to reach $6.7 billion by 2028.

This growth is predicted to be driven predominantly by adoption of maintenance therapy for the disease across the US, UK, France, Germany, Spain, Italy and Japan.

Healthcare industry could take up to five years to stabilise after no-deal Brexit

The healthcare industry could take up to five years to stabilise in the event of a no-deal Brexit, according to pharmaceutical industry professionals surveyed by GlobalData.

Two thirds (66%) of respondents in the US, EU and UK believed that it would take more than three years for the UK to stabilise its healthcare industry, compared to just 9% who thought stabilisation would occur in less than 12 months.

Heart failure market to quadruple in ten years to $16 billion

New research from intelligence firm GlobalData has indicated that the market for heart failure drugs is forecast to expand by more than four times in a single decade, growing from $3.7 billion in 2016 to $16.1 billion in 2026 across the seven key markets: US, UK, France, Germany, Spain, Italy and Japan – a compound annual growth rate of 15.7%.

Non-small cell lung cancer market to hit $26bn by 2025

New research from GlobalData has indicated that the non-small cell lung cancer (NSCLC) market will rise in value by over 300% from $6.21 billion in 2015 to $26.71 billion in 2025 across the eight major markets (US, France, Germany, Italy, Spain, the UK, Japan and China); a 15.7% compound annual growth rate.

UAE’s pharmaceutical market projected to grow from $3 billion to $5.7 billion by 2020

United Arab Emirates’ pharmaceutical market is set for growth of 13% annually to reach $5.7 billion by 2020, up from just over $3 billion in 2015. GlobalData has delivered this growth figure based on “increased healthcare expenditure, mandatory health insurance, and growing medical tourism”.

Acute coronary syndrome market to grow to over $12 billion by 2022

The acute coronary syndrome (ACS) market is forecast to rise from $7.8 billion in 2015 to $12.1 billion by 2022 with a compound annual growth rate of 4.6%, research and consulting firm GlobalData predicts.

EU referendum outcome will have major consequences for UK’s pharma sector - GlobalData

The outcome of today’s referendum on the UK’s continuing membership of the European Union (EU) will have major consequences for the country’s pharmaceutical and medical device sectors, according to research and consulting firm GlobalData.

For the pharmaceutical and medical device industries, a vote to leave would have significant consequences in five key areas including, regulatory impacts, research and development, access to talent, intellectual property rights, and market access.

Indian pharma market set to grow to $55 billion by 2020

Dr Reddy's is well positioned to benefit from global biosimilar growth

The pharmaceuticals market in India, valued at $20 billion in 2015, is set to soar to $55 billion by 2020, growing at 22.4% CAGR to the end of the decade, says research and consulting firm GlobalData.

According to the company’s latest report, entitled ‘CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – India’, the country’s rapidly growing generics market will be the primary driver of the pharmaceutical sector growth, with sales expected to rise by nearly 84% to $26.1 billion in 2016.

Pharma deals crucial to cutting R&D costs

With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster status, deal-making is becoming increasingly vital for pharma companies to offset rising R&D costs, industry analysts say.

 A report by business intelligence provider GBI Research finds that pharma companies are considering various strategies to overcome the current challenges in the market: rising R&D costs, a tighter regulatory environment – such as changes to patent laws – and the struggling global economy, with

Lung cancer market to hit $10.9bn by 2021

lung cancer x ray

The global market value for non-small cell lung cancer treatment will rise from $6.9 billion in 2014 to $10.9 billion by 2021, new industry figures show.

An analysis by market intelligence firm GBI Research has found the non-small cell lung cancer (NSCLC) market will achieve a compound annual growth rate of 8.5%. The growth will mostly driven by growth across in the US, Canada, UK, Germany, France, Italy, Spain and Japan.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches